Analgesic effects of nerve growth factor‐directed monoclonal antibody on diabetic neuralgia in an animal model
Sign Up to like & getrecommendations! Published in 2022 at "FEBS Open Bio"
DOI: 10.1002/2211-5463.13410
Abstract: Current treatment options for diabetic neuralgia are limited and unsatisfactory. Tanezumab, a monoclonal antibody that blocks nerve growth factor (NGF) signaling, has been shown to be effective in relieving the clinical symptoms of osteoarthritis pain,… read more here.
Keywords: monoclonal antibody; diabetic neuralgia; nerve growth; growth factor ... See more keywords